Levosimendan (trade name Simdax) is a novel and potent calcium sensitizer that has been used in the management of acutely decompensated congestive heart failure.It has a two fold mechanism of action. It leads to greater ionotrophy by increasing the calcium sensitivity as it binds to Troponin and this results in a greater positive iontrophic force. Secondly, the drug is able to open ATP sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased pre-load and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved yet.

纯度：≥98%

CAS：141505-33-1